±±¾©Èü³µpk10

Boots Healthcare International (BHI) has split its top marketing

job into two roles and appointed Alberto Culver vice-president of

international marketing, Barton Warner, to the new position of strategic

marketing director.

The shake-up is designed to relieve the pressure on Phil Davey, BHI's

director of worldwide business operations. Davey's title has now been

changed to chief operating officer.

Warner's move echoes that of Paul Stoneham, former Alberto Culver

president, who becomes managing director of BHI in August. Both Warner

and Davey will report directly to Stoneham.

Warner said his role would be one of "classic brand development", with

responsibility for the global marketing of BHI brands such as Strepsils,

Nurofen, E45, and Clearasil.

Davey said the new structure is the same as existed a year ago, before

then-strategic marketing director Rob Morgan moved within the Boots

empire to head strategy in the projects unit.

After Morgan's departure, Davey took responsibility for strategic

marketing as well as operations. But BHI's subsequent acquisition of

Clearasil added the US and Japan to the list of markets Davey oversees.

"It was impossible for me to cover those as well as do strategic

marketing," he said. "So we decided to go back to two roles."

A year ago, Alberto Culver, owner of the VO5 and St Ives Swiss Formula

haircare brands, poached Warner from Johnson & Johnson, where he was

franchise marketing director for Europe, Africa and the Middle East.

Before joining J&J, he held several beauty care marketing positions at

Procter & Gamble.

The UK advertising account for the VO5 brand changed hands twice under

Warner. It moved from Lowe Lintas to M&C Saatchi. Four months later Euro

RSCG Wnek Gosper got the dollars 40m (pounds 29m) international business

without a pitch.

Brent Shakeshaft has replaced Warner in the post of international

marketing vice-president.